Elevated High-Sensitivity C-Reactive Protein Levels Predict Decreased Survival for Nasopharyngeal Carcinoma Patients in the Intensity-Modulated Radiotherapy Era

Lin Quan Tang1,2*, Dong Peng Hu3*, Qiu Yan Chen1,2, Lu Zhang1,2, Xiao Ping Lai3, Yun He3, Yun-Xiu-Xiu Xu3, Shi-Hua Wen3, Yu-Tuan Peng3, Wen-Hui Chen1, Shan-Shan Guo1,2, Li-Ting Liu1,2, Chao-Nan Qian1,2, Xiang Guo1,2, Mu-Sheng Zeng1,2*, Hai-Qiang Mai1,2*

1 State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China, 2 Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China, 3 ZhongShan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, China

☯ These authors contributed equally to this work.
* zengmsh@mail.sysu.edu.cn (MSZ); maihq@mail.sysu.edu.cn (HQM)

Abstract

Purpose
This study aimed to clarify the prognostic utility of high-sensitivity C-reactive protein (hs-CRP) in nasopharyngeal carcinoma (NPC) patients in the Intensity-Modulated Radiotherapy (IMRT) era.

Patients and Methods
In this observational study, 1,589 non-metastatic NPC patients treated with IMRT were recruited. Blood samples were collected before treatment for examination of hs-CRP levels. We evaluated the association of pretreatment hs-CRP levels with overall survival rate (OS), progression free survival rate (PFS), locoregional relapse free survival rate (LRFS) and distant metastasis free survival rate (DMFS).

Results
Baseline hs-CRP levels were correlated with sex, clinical stage, body mass index, smoking status, and EBV DNA level. Multivariate analysis showed that hs-CRP had significant association with OS (HR: 1.723; 95%CI: 1.238–2.398; p = 0.001), PFS (HR: 1.621; 95%CI: 1.273–2.064; p < 0.001) and DMFS (HR: 1.879; 95%CI: 1.394–2.531; p < 0.001). In subgroups such as advanced-stage group, low EBV DNA group and high EBV DNA group, elevated hs-CRP levels still predicted poor clinical outcomes. Furthermore, in patients with chronic HBV infection, decreased 4-year survival was observed in the cohort of high hs-CRP levels, with 87.4% vs. 94.9% (p = 0.023) for OS, 65.2% vs. 90.8% (p<0.001) for PFS, and 67.6% vs.
95.0% (p < 0.001) for DMFS. A similar finding was observed for patients with cardiovascular disease, with 79.1% vs. 90.2% (p = 0.020) for PFS, and 71.4% vs. 97.6% (p = 0.002) for DMFS.

**Conclusion**

Elevated serum hs-CRP levels were correlated with poor survival for NPC patients in the IMRT era, playing a complementary role to TNM stage and EBV DNA. In addition, elevated hs-CRP level was still an effective indicator for patients with chronic HBV infection and cardiovascular disease.

**Introduction**

Nasopharyngeal carcinoma (NPC) is a head and neck neoplasm of high malignancy, with an extremely skewed distribution across the world. Being endemic in Southeast Asia, it has brought obvious devastation to societies because the peak incidence is at 40 to 50 years of age. Radiotherapy with or without chemotherapy is the primary treatment modality for NPC patients, and 5-year overall survival exceeding 75% can be achieved today [1]. Recently, great achievements in biomarker’s finding and improved treatment methods were successively reported in the battle against NPC, such as plasma Epstein-Barr virus DNA [2] and serum lactate dehydrogenase (LDH) [3], having been identified to be of significant value in refining treatment strategies and predicting outcomes. In particular, plasma EBV DNA has been considered to be a marvelous indicator for the diagnosis, risk stratification, monitoring and prediction of the prognosis of NPC [4–8], and it has been gradually implemented in clinical practice since 2004 when its excellent prognostic value for NPC patients was discovered [7].

In the 21st century, the diagnostic and treatment allocation for NPC has undergone tremendous changes. Intensity-modulated radiotherapy (IMRT) has gradually replaced two-dimensional conventional radiotherapy (2D-CRT) as the primary means of radiotherapy, gaining superior locoregional control [9] and improved long-term survival for patients with NPC [10]. Therefore, it is of interest to determine whether prognostic factors previously evaluated for 2D-CRT can also be applied to modern IMRT. We hypothesize that some extra biomarkers may be complementary to EBV DNA in IMRT.

High-sensitivity C-reactive protein (hs-CRP), an acute phase protein synthesized by the liver, was demonstrated to be correlated with a poorer prognosis in colorectal cancer [11], osteosarcoma [12], hepatocellular carcinoma [13] and other cancers [14], as well as for NPC patients [15]. Besides, previous studies have also proved that patients with cardiovascular disease and chronic hepatitis display increased serum hs-CRP levels [16, 17]. It was perceived that CRP could deposit in arterial intima and recruit monocytes during atherogenesis [18]. While in chronic hepatitis, HBV may enhance the expression of IL-6 [19] and IL-6 would in turn promote the production of CRP [20].

However, findings from previous reports [15] showing the relationship between elevated CRP levels and poor survival for NPC patients were based on two-dimensional radiotherapy (2D-CRT) with a moderate sample size and without adjusting for other factors such as body mass index (BMI) [21], concurrent disease, and smoking status. The prognostic role of baseline hs-CRP levels in patients with NPC treated with IMRT remains unknown.

Therefore, we conducted a large-scale cohort study aimed at examining the role of hs-CRP in prognosis for NPC patients treated with IMRT. Subgroup analyses were also performed in...
low EBV DNA and high EBV DNA subgroups and in patients with or without comorbidities of cardiovascular disease and chronic HBV infection, evaluating whether hs-CRP still had prognostic value or not when confined to groups mentioned above.

Patients and Methods

Patients

NPC patients treated with IMRT were consecutively recruited from Jan 2007 to Dec 2010. Patients were excluded if they met the following criteria: (1) previously received any anticancer therapy; (2) <18 years old; (3) pregnant or lactating; (4) unsuitable for chemotherapy as a result of a liver, kidney, lung, or heart deficiency; (5) a history of previous or synchronous malignant tumors; (6) NPC patients with primary metastasis; or (7) lost during follow-up.

The routine staging work-up included clinical examination of the head and neck region, a magnetic resonance imaging scan from the suprasellar cistern to the collarbone, fiberoptic nasopharyngoscopy, chest radiography, and abdominal sonography and a whole-body bone scan or whole-body FDG PET/CT. All the patients were restaged according to the seventh American Joint Committee on Cancer (AJCC) TNM staging manual. The technique of IMRT has been described in detail [22], and relevant assessments have been continuously reported in anticancer therapy [23, 24].

Methods

This study was approved by the independent Institute Research Ethics Committee at the Sun Yat-sen University Cancer Center (SYSUCC, Guangzhou, P. R. China), and written consents were obtained from all participants. Before treatment, the following baseline information was collected: sex, age, hereditary NPC, smoking status, and BMI. Information on concurrent diseases, such as cardiovascular disease, diabetes mellitus, or chronic HBV infection, was also collected as previous studies have indicated that these factors may promote increased serum CRP levels [16, 17]. These comorbidities and smoking status were defined as follows: Chronic hepatitis B: HBsAg-positive >6 months and serum HBV-DNA ≥2000 IU/ml (10^4 copies/mL) with or without elevated alanine transaminase/aspartate transaminase levels; diabetes: fasting plasma glucose level 7.0 mmol/L and/or 2 h plasma glucose level 11.1 mmol/L after a 75 g glucose load or a previous diagnosis of diabetes by a healthcare professional; cardiovascular disease: includes coronary heart disease, cerebro-vascular disease, peripheral arterial disease, rheumatic heart disease, congenital heart disease, deep vein thrombosis, pulmonary embolism, hypertension (systolic blood pressure 140 mmHg, diastolic blood pressure 90 mmHg) or a previous diagnosis of any of these diseases by a healthcare professional; smoking status: patients were identified as current, former, or never smokers. Patients who smoked or reported smoking cessation within 1 year of the diagnosis were considered current smokers. Patients who had smoked less than 100 cigarettes during their lifetime were considered never smokers.

Hs-CRP and EBV DNA measurement

A 3 mL fasting blood sample was collected before treatment. The sample was processed within 3 hours of collection, and serum was stored at -70 to -80°C until analysis. Hs-CRP was determined with immune-turbidometric assay using a HITACHI Automatic Analyzer LABOSPECT008 (Hitachi High-Technologies Corporation, Tokyo, Japan) [25]. Interassay coefficients of variation were less than 5% for hs-CRP. Plasma EBV DNA concentrations were routinely measured using q-PCR before treatment. EBV-specific VCA/IgA antibodies and EBV-specific EA/IgA antibodies were measured using an immunoenzymic assay described previously [26].
Statistical analysis

Our primary endpoint was overall survival (OS). Progression-free survival (PFS), locoregional relapse-free survival (LRFS) and distant metastasis-free survival (DMFS) were included as secondary endpoints in this article. OS was calculated from the date of the first NPC diagnosis to the date of death from any cause or patient censoring at the date of the last follow-up. PFS was calculated from the date of the first NPC diagnosis to the date of relapse at any site or patient censoring at the date of the last follow-up. LRFS was calculated from the date of the first NPC diagnosis to the date of relapse at head and neck region or patient censoring at the date of the last follow-up. DMFS was determined from the date of the first NPC diagnosis to the date of distant relapse or patient censoring at the date of the last follow-up.

Patients who were still alive as of December of 2013 (end of follow-up) and those who were lost to follow-up were censored at the date of the last contact. After treatment was completed, the patients were evaluated at 3-month intervals for the first 3 years and every 6 months thereafter.

All statistical analyses were performed using SPSS 17.0 (SPSS Inc., Chicago, IL). A Mann-Whitney test was used to detect differences in subgroup analysis. Receiver operating characteristic (ROC) curves served to develop the optimal cutoff point for serum hs-CRP levels concerning OS, PFS, LRFS, DMFS (S1 Fig). The score localized closest to the point at both maximum sensitivity and specificity was selected as the cutoff score leading to the greatest number of cancers that were correctly classified as having or not having the outcome. Here, hs-CRP cutoff points for OS, PFS, LRFS, and DMFS were 1.96 mg/L, 1.96 mg/L, 3.23 mg/L, and 1.96 mg/L, respectively. We then selected 1.96 mg/L as the hs-CRP cutoff point in our study. The Kaplan-Meier method was employed to estimate the cumulative survival plot. The survival between groups (hs-CRP > 1.96 mg/L vs. hs-CRP ≤ 1.96 mg/L) was compared using the log-rank test. Multivariate analysis was achieved using a Cox proportional hazards model, excluding insignificant variables by backward elimination. Factors that might have an impact on outcomes, such as age (>45 years vs. ≤45 years), sex (male vs. female), histology (III vs. II vs. I), tumor stage (T4 vs. T3 vs. T2 vs. T1), node stage (N3 vs. N2 vs. N1 vs. N0), treatment method (chemoradiotherapy vs. radiotherapy), BMI (≥23 kg/m2 vs. <23 kg/m2), smoking status (ever and current vs. never), chronic HBV infection (yes vs. no), diabetes mellitus (yes vs. no), cardiovascular disease (yes vs. no), family history of NPC (yes vs. no), EBV DNA (>4000 copies/ml vs. ≤4000 copies/ml), VCA-IgA (>1:80 vs. ≤1:80), and EA-IgA (>1:10 vs. ≤1:10), were all adjusted in a Cox proportional hazards model. All reported probability values were two-tailed, and P < 0.05 was considered statistically significant.

Results

Patient characteristics

The characteristics of the 1,589 NPC patients are listed in Table 1. In total, there were 252 (15.9%) early stage (I-II) NPC patients and 1,337 (84.1%) advanced stage (III-IV) patients in the cohort. All patients were treated according to the principles of treatment for NPC patients at Sun Yat-sen University Cancer Center, Guangzhou, China. A stratified, multi-therapeutic protocol was used. In all, radiation alone was administered for 235 (14.8%) patients, and radiation with concurrent platinum-based chemotherapy was administered for 648 (40.8%) individuals. 484 (30.5%) patients received concurrent chemoradiotherapy with neoadjuvant and 156 (9.8%) were treated with radiation plus neoadjuvant. Moreover, 52 (3.3%) received concurrent chemoradiotherapy with adjuvant and 14 (0.9%) completed concurrent chemoradiotherapy with both neoadjuvant and adjuvant. Neoadjuvant or adjuvant chemotherapy consisting of
Table 1. Patient Characteristics.

| Characteristics                        | n(%)       | hs-CRP, mg/L | P value |
|----------------------------------------|------------|--------------|---------|
|                                        |            | ≤1.96 | >1.96 |
| Age(y)                                 |            |       |       |
| ≤45                                    | 828 (52.1) | 518   | 310   | 0.417 |
| >45                                    | 761 (47.9) | 461   | 300   |       |
| Sex                                    |            |       |       |
| Male                                   | 1162 (26.9)| 681   | 481   | <0.001|
| Female                                 | 427 (73.1) | 298   | 129   |       |
| Histology, WHO type                    |            |       |       |
| I                                      | 2 (0.1)    | 1     | 1     | 0.751 |
| II                                     | 78 (4.9)   | 51    | 27    |       |
| III                                    | 1509 (95.0)| 927   | 582   |       |
| Clinical stagea                        |            |       |       |
| I                                      | 65 (4.1)   | 57    | 8     | <0.001|
| II                                     | 187 (11.8) | 138   | 49    |       |
| III                                    | 870 (54.8) | 555   | 315   |       |
| IV A-B                                 | 467 (29.4) | 229   | 238   |       |
| Tumor stagea                           |            |       |       |
| T1                                     | 140 (8.8)  | 109   | 31    | <0.001|
| T2                                     | 312 (19.6) | 229   | 83    |       |
| T3                                     | 763 (48.0) | 472   | 291   |       |
| T4                                     | 374 (23.5) | 169   | 205   |       |
| Node stagea                            |            |       |       |
| N0                                     | 307 (19.3) | 201   | 106   | 0.033 |
| N1                                     | 548 (34.5) | 353   | 195   |       |
| N2                                     | 610 (38.4) | 349   | 261   |       |
| N3                                     | 124 (7.8)  | 76    | 48    |       |
| Treatment                              |            |       |       |
| Radiotherapy                           | 235 (14.8) | 173   | 62    | <0.001|
| Chemoradiotherapy                      | 1354 (85.2)| 806   | 548   |       |
| Body mass indexb, kg/m²                |            |       |       |
| <18.5                                  | 123(7.7)   | 81    | 42    | <0.001|
| 18.5–22.9                              | 678(42.7)  | 446   | 232   |       |
| 23.0–27.4                              | 663(41.7)  | 398   | 265   |       |
| ≥27.5                                  | 125(7.9)   | 54    | 71    |       |
| Smoking status                         |            |       |       |
| Never                                  | 999(62.9)  | 647   | 352   | 0.001 |
| Ever or current                        | 590(37.1)  | 332   | 258   |       |
| Chronic HBV infection                  |            |       |       |
| No                                     | 1458(91.8) | 898   | 560   | 0.957 |
| Yes                                    | 131(8.2)   | 81    | 50    |       |
| Diabetes mellitus                      |            |       |       |
| No                                     | 1548(97.4) | 954   | 594   | 0.932 |
| Yes                                    | 41(2.6)    | 25    | 16    |       |
| Cardiovascular disease                 |            |       |       |
| No                                     | 1494(94.0) | 937   | 557   | <0.001|
| Yes                                    | 95(6.0)    | 42    | 53    |       |

(Continued)
cisplatin plus 5-fluorouracil or cisplatin plus taxane was administered every 3 weeks for 2 or 3 cycles [27]. Concurrent cisplatin chemotherapy was administered on weeks 1, 4, and 7 of RT. The median follow-up time was 44 months (IQR: 38–57). To the last date of follow-up, 67 of the 979 patients in the low hs-CRP (≤1.96 mg/L) group (6.8%) and 86 of the 610 patients in the high hs-CRP (>1.96 mg/L) group (14.1%) were dead. Worse outcomes, such as cancer progression (22.5% vs. 13.6%; p < 0.001) and distant metastasis (17.5% vs. 8.4%; p < 0.001) could be observed in the high hs-CRP group compared with low hs-CRP group.

We also found that patients with high hs-CRP levels displayed worse 4-year OS (86.4% vs. 93.5%; p<0.001), PFS (76.1% vs. 86.5%; p<0.001) and DMFS (81.1% vs. 91.9%; p<0.001) but not worse LRFS than did patients with low hs-CRP levels (Fig 1). Additionally, the 4-year cancer-specific survival rates were 86.9% and 94.1% for the high hs-CRP cohort and the low hs-CRP cohort, respectively (p<0.001).

### The relationship between baseline hs-CRP and other risk factors

As presented in detail in Table 1, the pretreatment serum hs-CRP level was correlated with sex, clinical stage, body mass index, smoking status, and EBV DNA level. Pretreatment serum hs-CRP levels for patients with advanced stage (median: 1.39 mg/L; IQR: 0.64–3.50 mg/L) NPC were significantly higher than those for early stage (median: 0.86 mg/L; IQR: 0.42–1.83 mg/L) patients (p<0.001). Compared to patients with EBV DNA ≤ 4000 copies/ml (median:}

---

**Table 1. (Continued)**

| Characteristics          | n(%) | hs-CRP, mg/L | P value |
|--------------------------|------|--------------|---------|
|                          |      | ≤1.96 | >1.96    |         |
| Family history of NPC    |      |       |          |         |
| No                       | 1395(87.8) | 853 | 542 | 0.308 |
| Yes                      | 194(12.2) | 126 | 68 |      |
| EBV DNA, copies/ml       |      |       |          |         |
| ≤4000                    | 894(56.3) | 596 | 298 | <0.001 |
| >4000                    | 695(43.7) | 383 | 312 |      |
| VCA-IgA                  |      |       |          |         |
| ≤1:80                   | 408(25.7) | 263 | 145 | 0.170 |
| >1:80                   | 1181(74.3) | 716 | 465 |      |
| EA-IgA                  |      |       |          |         |
| ≤1:10                   | 658(41.4) | 418 | 240 | 0.187 |
| >1:10                   | 931(58.6) | 561 | 370 |      |
| Total                   | 1589(100%) | 979(61.6) | 610(38.4) |      |

Abbreviations: WHO = World Health Organization; HBV = hepatitis B virus; NPC = nasopharyngeal carcinoma; VCA = viral capsid antigen; EA = early antigen; Deaths = deceased patients at the last follow-up; Non-Deaths = patients alive at the last follow-up. PR = patients who progressed at the last follow-up; Non-PR = patients who had not progressed at the last follow-up; DM = patients presenting with distant metastasis at the last follow-up; Non-DM = patients without distant metastasis at the last follow-up. LR = patients presenting with local or regional relapse at the last follow-up; Non-LR = patients without local or regional relapse at the last follow-up.

P value was calculated with Pearson χ² Test

*According to American Joint Committee on Cancer, 7th edition.

*Different intervals for body mass index were divided according to the World Health Organization classifications for Asian populations.

*using Fisher’s Exact Test.

[10.1371/journal.pone.0122965.t001]

---

PLOS ONE DOI:10.1371/journal.pone.0122965 April 13, 2015 6/17
In the study population, Kaplan-Meier survival curves were used to compare overall survival rates (A), progression-free survival rates (B), locoregional relapse-free survival (C) and distant metastasis-free survival rates (D) in the entire cohort of NPC patients. The hazards ratios (HRs) were calculated using the unadjusted Cox proportional hazards model, and P values were calculated using the unadjusted log-rank test.

Fig 1. Kaplan-Meier survival curves for the low hs-CRP group (<1.96 mg/L) and the high hs-CRP group (>1.96 mg/L) in the study population. Overall survival rates (A), progression-free survival rates (B), locoregional relapse-free survival (C) and distant metastasis-free survival rates (D) were compared in the entire cohort of NPC patients. Hazards ratios (HRs) were calculated using the unadjusted Cox proportional hazards model. P values were calculated using the unadjusted log-rank test.

doi:10.1371/journal.pone.0122965.g001

1.08 mg/L; IQR: 0.53–2.56 mg/L), those who had EBV DNA > 4000 copies/ml (median: 1.63 mg/L; IQR: 0.74–4.20 mg/L) were inclined to present with high hs-CRP levels (p<0.001).

In addition, significant differences in hs-CRP levels could be found between the groups with (median: 1.63 mg/L; IQR: 0.70–4.00 mg/L) and without (median: 1.09 mg/L; IQR: 0.56–
2.84 mg/L) smoking history (p<0.001) and those with (median: 2.27 mg/L; IQR: 0.90–5.31 mg/L) and without (median: 1.22 mg/L; IQR: 0.59–3.01 mg/L) cardiovascular disease (p<0.001). However, no significant differences were detected between the groups with and without chronic HBV infection or diabetes mellitus.

Univariate and multivariate analyses showed that hs-CRP was a predictor of clinical outcomes

Univariate analysis indicated that in addition to elevated hs-CRP levels, age, sex, TNM classification, smoking status, concurrent cardiovascular disease, high EBVDNA, and treatment allocation were significantly associated with worse survival for NPC patients (S1 Table).

In a multivariate analysis, after adjusting for other risk factors, hs-CRP was still an independent prognostic factor for OS (P = 0.001), PFS (P<0.001) and DMFS (P<0.001). Higher levels of hs-CRP predicted worse OS (HR: 1.723; 95%CI:1.238–2.398; p = 0.001), PFS (HR: 1.621; 95%CI: 1.273–2.064) and DMFS (HR: 1.879; 95%CI: 1.394–2.531) (Table 2).

Prognostic significance of the hs-CRP within the UICC TNM classification and EBV DNA subgroup

As shown in Table 3, when 4-year survival rates were calculated in specific subgroups, statistical significance was detected especially for the advanced-stage (III-IV) group, the low EBV DNA (≤4000 copies) group and the high EBV DNA (>4000 copies) group (Fig 2), but not for patients with early-stage (I-II) disease.

These results indicated that hs-CRP levels might play a complementary role to TNM stage and EBV DNA levels, facilitating more accurate prognostic stratification of NPC patients.

Prognostic significance of hs-CRP for patients with chronic HBV infection and cardiovascular disease

We evaluated whether hs-CRP is still an effective prognostic indicator for NPC patients with cardiovascular disease and chronic hepatitis. Interestingly, we found that hs-CRP levels were good at survival prediction for the NPC patients with chronic HBV infection. Compared with patients with low hs-CRP levels, decreased survival was detected in the cohort of high hs-CRP, with 87.4% vs. 94.9% (p = 0.023) for OS, 65.2% vs. 90.8% (p<0.001) for PFS, and 67.6% vs. 95.0% (p<0.001) for DMFS (Table 3 and Fig 3). A similar finding was observed for patients with cardiovascular disease, with 79.1% vs. 90.2% (p = 0.020) for PFS, and 71.4% vs. 97.6% (p = 0.002) for DMFS (Table 3 and Fig 4).

Discussion

With an observational study of 1,589 NPC patients in the IMRT era, elevated hs-CRP levels were correlated with worse OS, PFS and DMFS but not worse LRFS. Higher levels of pretreatment hs-CRP predicted poorer prognosis, playing a complementary role to TNM stage and plasma EBV DNA levels.

Hs-CRP, as an acute-phase protein, is a non-specific protein reacting to acute inflammation, infection, and tissue damage. When an acute-phase response happens, cytokines, predominantly IL-6, coming from the injured tissue will promote the synthesis of hs-CRP in the liver [20]. Epidemiological studies found that hs-CRP had a robust association with coronary heart disease (CHD) over the last decade [28]. In recent years, hs-CRP has become a popular biomarker for the prediction of clinical outcomes in cancer patients. High hs-CRP levels were considered to indicate an unfavorable prognosis for patients with colorectal cancer [11].
osteosarcoma [12], hepatocellular carcinoma [13], prostate cancer [29] and renal cell carcinoma [30]. Recently, Xia reported that the combination of hs-CRP and N-classification could improve the prognostic stratification for NPC patients based on only two-dimensional conventional radiotherapy [15]. Currently, IMRT is widely used in clinical practice for NPC treatment, greatly contributing to reduced local and regional relapse. Interestingly, according to our findings and consistent with previous reports, our study confirmed that pretreatment serum hs-CRP is still an independent prognostic factor for NPC patients in the IMRT era.

Over the last decade, plasma EBV DNA levels have been found to be correlated with tumor burden [31], TNM stage [32], response to chemoradiotherapy [32–34], and survival in NPC patients [6, 7]. It is now a useful biomarker for the clinical management of NPC patients and is

Table 2. Multivariate analysis of prognostic factors for NPC patients.

| Outcomes | Number of events (%) | Variable | p       | HR     | 95% CI for HR lower | upper |
|----------|----------------------|----------|---------|--------|---------------------|-------|
| OS       | 153 (9.6)            | Age      | 0.003   | 1.666  | 1.189               | 2.334 |
|          |                      | Sex      | 0.057   | 1.485  | 0.988               | 2.230 |
|          |                      | Tumor stage | 0.008 | 1.346  | 1.082               | 1.675 |
|          |                      | Node stage | 0.000 | 1.448  | 1.182               | 1.772 |
|          |                      | BMI      | 0.000   | 0.529  | 0.378               | 0.740 |
|          |                      | Cardiovascular disease | 0.060 | 1.660  | 0.979               | 2.814 |
|          |                      | EBV DNA  | 0.000   | 2.841  | 1.938               | 4.164 |
|          |                      | hs-CRP   | 0.001   | 1.723  | 1.238               | 2.398 |
| PFS      | 270 (17.0)           | Sex      | 0.046   | 1.342  | 1.006               | 1.789 |
|          |                      | Node stage | 0.000 | 1.325  | 1.142               | 1.538 |
|          |                      | BMI      | 0.000   | 0.515  | 0.401               | 0.662 |
|          |                      | EBV DNA  | 0.000   | 3.147  | 2.382               | 4.159 |
|          |                      | hs-CRP   | 0.000   | 1.621  | 1.273               | 2.064 |
| LRFS     | 99 (6.2)             | BMI      | 0.005   | 0.559  | 0.371               | 0.842 |
|          |                      | EBV DNA  | 0.000   | 2.550  | 1.689               | 3.852 |
| DMFS     | 189 (11.9)           | Sex      | 0.014   | 1.574  | 1.095               | 2.262 |
|          |                      | Tumor stage | 0.068 | 1.189  | 0.987               | 1.433 |
|          |                      | Node stage | 0.000 | 1.555  | 1.292               | 1.872 |
|          |                      | BMI      | 0.000   | 0.562  | 0.418               | 0.756 |
|          |                      | EBV DNA  | 0.000   | 3.049  | 2.163               | 4.299 |
|          |                      | hs-CRP   | 0.000   | 1.879  | 1.394               | 2.531 |

Abbreviations: CI = confident interval; HR = hazard ratio; OS = overall survival; BMI = body mass index; LRFS = locoregional relapse free survival; DMFS = distant metastasis free survival; other abbreviations are the same as Table 1.

A Cox proportional hazards regression model was used to detect variables one by one without adjustment. All variables were transformed into category variables. HRs were calculated for age (>45 years vs. ≤45 years), sex (male vs. female), histology (III vs. II vs. I), tumor stage (T4 vs. T3 vs. T2 vs. T1), node stage (N3 vs. N2 vs. N1 vs. N0), treatment method (chemoradiotherapy vs. radiotherapy), BMI (≥23 kg/m² vs. <23 kg/m²), smoking status (ever and current vs. never), Chronic hepatitis B (yes vs. no), diabetes mellitus (yes vs. no), cardiovascular disease (yes vs. no), family history of NPC (yes vs. no), EBV DNA (>4000 copies/ml vs. ≤4000 copies/ml), VCA-IgA (>1:80 vs. ≤1:80), EA-IgA (>1:10 vs. ≤1:10) and hs-CRP (>1.96 mg/L vs. ≤1.96 mg/L).

According to American Joint Committee on Cancer, 7th edition

According to the World Health Organization classifications for Asian populations

doi:10.1371/journal.pone.0122965.t002
considered the most powerful biomarker to complement TNM stage [2]. Intriguingly, we found that pretreatment hs-CRP levels were complementary to EBV DNA levels to predict prognosis for NPC patients. These results indicate that EBV DNA levels alone are insufficient to complement the TNM classification. Most likely because of the biological heterogeneity of cancer, large variations in the clinical outcomes can be found in NPC patients with the same stage and similar treatment regimens, as well as even with the same EBV DNA level.

The mechanism to explain why the combination of these two biomarkers will improve the prognostic stratification of NPC patients is unclear. Previous studies demonstrated that EBV DNA molecules are released into the circulation by apoptosis and represent the tumor load

**Table 3. Four-year survival rate for patients in specific subgroups.**

| Outcomes | Subgroups            | Four-year survival rate (95%CI), % | P value |
|----------|----------------------|------------------------------------|---------|
|          | hs-CRP ≤ 1.96mg/L    | hs-CRP > 1.96mg/L                  |         |
| OS       | Clinical stage-IIb   | 97.9 (95.9–99.9)                   | 93.4 (85.8–100.0) | 0.289 |
|          | Clinical stage-IIIb/Vb | 92.4 (90.4–94.4)                  | 85.7 (82.6–88.8)   | <0.001 |
|          | Low EBV DNA          | 96.8 (95.4–98.2)                   | 94.1 (91.4–96.8)   | 0.019 |
|          | High EBV DNA         | 88.2 (84.7–91.7)                   | 79.1 (74.0–84.2)   | 0.001 |
|          | Chronic HBV          | 94.9 (89.0–100.0)                  | 87.4 (78.0–96.8)   | 0.023 |
|          | CVD                  | 90.2 (81.0–99.4)                   | 79.1 (68.1–90.1)   | 0.127 |
| PFS      | Clinical stage-IIb   | 93.9 (90.4–97.4)                   | 87.2 (78.4–96.0)   | 0.091 |
|          | Clinical stage-IIIb/Vb | 84.7 (82.2–87.2)                  | 75.0 (71.1–78.9)   | <0.001 |
|          | Low EBV DNA          | 92.8 (90.6–95.0)                   | 89.8 (86.3–93.3)   | 0.210 |
|          | High EBV DNA         | 76.7 (72.4–81.0)                   | 63.0 (57.1–68.9)   | <0.001 |
|          | Chronic HBV          | 90.8 (84.3–97.3)                   | 65.2 (50.1–80.3)   | <0.001 |
|          | CVD                  | 92.7 (84.7–100.0)                  | 69.9 (56.6–83.2)   | 0.020 |
| LRFS     | Clinical stage-IIb   | 96.6 (88.6–100.0)                  | 90.8 (83.2–98.4)   | 0.083 |
|          | Clinical stage-IIIb/Vb | 93.2 (91.4–95.0)                  | 93.1 (90.7–95.5)   | 0.969 |
|          | Low EBV DNA          | 95.7 (93.9–97.5)                   | 96.8 (94.8–98.8)   | 0.408 |
|          | High EBV DNA         | 91.0 (88.1–93.9)                   | 88.8 (84.7–92.9)   | 0.395 |
|          | Chronic HBV          | 96.1 (91.8–100.0)                  | 93.5 (86.4–100.0)  | 0.346 |
|          | CVD                  | 93.7 (84.9–100.0)                  | 94.0 (87.3–100.0)  | 0.743 |
| DMFS     | Clinical stage-IIb   | 96.9 (94.4–99.4)                   | 94.6 (88.7–100.0)  | 0.527 |
|          | Clinical stage-IIIb/Vb | 90.6 (88.4–92.8)                  | 79.7 (76.0–83.4)   | 0.001 |
|          | Low EBV DNA          | 96.3 (94.7–97.9)                   | 91.8 (88.5–95.1)   | 0.015 |
|          | High EBV DNA         | 84.8 (81.1–88.5)                   | 70.9 (65.4–76.4)   | <0.001 |
|          | Chronic HBV          | 95.0 (90.1–99.9)                   | 67.6 (52.9–82.3)   | <0.001 |
|          | CVD                  | 97.6 (92.9–100.0)                  | 71.4 (58.1–84.7)   | 0.002 |

Abbreviations: CI = confident interval; HR = hazard ratio; OS = overall survival; CVD = cardiovascular disease; LRFS = locoregional relapse free survival; DMFS = distant metastasis free survival; other abbreviations are the same as Table 1.

Low EBV DNA means EBV DNA <4000 copies/ml, and high EBV DNA is EBV DNA >4000 copies/ml.
P value is calculated using log-rank method

aAccording to American Joint Committee on Cancer, 7th edition

doi:10.1371/journal.pone.0122965.t003
Tumor cells also express EBV-encoded LMP1, which was demonstrated to regulate the production of IL-6 in epithelial cells [37], and IL-6 is able to promote NPC progression [38] and increase hs-CRP levels [20]. These findings partially explain why EBV DNA levels

Fig 2. Kaplan-Meier survival curves for the low hs-CRP group (<1.96 mg/L) and the high hs-CRP group (>1.96 mg/L) in patients with high EBV DNA. Overall survival rates (A), progression-free survival rates (B), locoregional relapse-free survival (C) and distant metastasis-free survival rates (D) were compared in the subgroup of NPC patients with EBV DNA >4000 copies/ml. Hazards ratios (HRs) were calculated using the unadjusted Cox proportional hazards model. P values were calculated using the unadjusted log-rank test.

doi:10.1371/journal.pone.0122965.g002
may correlate with hs-CRP levels. However, the mechanism of elevated hs-CRP level promoted the progression for NPC patients still need to explore in future study.

Epidemiologists found that elevated CRP levels could be examined in patients with acute viral hepatitis [39], cardiovascular disease [17] and type 2 diabetes mellitus [40]. Consistent
with these epidemiological discoveries, we found that hs-CRP levels were significantly higher in NPC patients with cardiovascular disease. Interestingly, we also found that the prognostic
ability of hs-CRP was applicable to patients with cardiovascular disease when it came to PFS and DMFS.

It was reported that patients with chronic HBV infection represented worse outcomes [41]. Immunological dysfunction was considered the latent mechanism leading to an unfavorable prognosis of HBV-infected NPC patients in that report. Despite the presence of hepatitis, hs-CRP still acted as a reliable indicator for prognosis. However, the potential interaction between hs-CRP and concurrent disease, such as cardiovascular disease and chronic HBV infection, should be further explored.

The major disadvantage of our study is the single measurement of serum hs-CRP recorded from one single center. Although our cancer center treats a large number of NPC patients, these results need to be validated in other data sets. Another limitation is that the median follow-up time is 44 months, and patients must remain closely followed up and report 5-year follow-up results as available.

In conclusion, our study demonstrated that baseline serum hs-CRP levels were an independent prognostic factor for NPC patients treated with IMRT and the subgroup patients with cardiovascular disease and chronic HBV infection. Because the measurement of hs-CRP is established, a routinely measured blood-based parameter that is reproducibly detected without additional laborious efforts before use in clinical applications, we believe that hs-CRP could have a promising application in NPC management. In the future, we look forward to developing a nomogram combining plasma EBV DNA, hs-CRP, tumor host and facility related factors and clinical staging to identify high risk patients of relapse and more individualized treatment strategies would be catered according to these factors.

Supporting Information

S1 Dataset. Original data used for all statistical analyses in this article (SAV)

S1 Fig. Receiver operating characteristic (ROC) curves for hs-CRP. Pretreatment serum hs-CRP serves as a predictor of (A) death, (B) progression, (C) locoregional relapse, (D) distant metastasis. The area under the ROC curve (AUC) was calculated for each graph. (TIF)

S1 Table. Univariate analysis of prognostic factors for NPC patients. (DOC)

Acknowledgments

We would like to thank Dr. Eng-Huat Tan, Stephanie Wheeler, Karie Simpson, and the anonymous reviewers for useful comments and suggestions.

Author Contributions

Conceived and designed the experiments: LQT DPH. Performed the experiments: DPH QYC LZ XPL YH YXXX SHW YTP WHC SSG LTL. Analyzed the data: DPH. Contributed reagents/materials/analysis tools: MSZ HQM CNQ XG. Wrote the paper: DPH.

References

1. Lee AW, Ng WT, Chan YH, Sze H, Chan C, Lam TH. The battle against nasopharyngeal cancer. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology. 2012; 104(3):272–8. doi: 10.1016/j.radonc.2012.08.001 PMID: 22938727.
2. Song C, Yang S. A meta-analysis on the EBV DNA and VCA-IgA in diagnosis of Nasopharyngeal Carcinoma. Pakistan journal of medical sciences. 2013; 29(3):885–90. PMID: 24353651; PubMed Central PMCID: PMC3809314.

3. Zhou GQ, Tang LL, Mao YP, Chen L, Li WF, Sun Y, et al. Baseline serum lactate dehydrogenase levels for patients treated with intensity-modulated radiotherapy for nasopharyngeal carcinoma: a predictor of poor prognosis and subsequent liver metastasis. International journal of radiation oncology, biology, physics. 2012; 82(3):e359–65. doi: 10.1016/j.ijrobp.2011.06.1967 PMID: 22000748.

4. Chan AT, Lo YM, Zee B, Chan LY, Ma BB, Leung SF, et al. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. Journal of the National Cancer Institute. 2002; 94(21):1614–9. PMID: 12419787.

5. Leung SF, Chan AT, Zee B, Ma B, Chan LY, Johnson PJ, et al. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type. Cancer. 2003; 98(2):288–91. doi: 10.1002/cncr.11496 PMID: 12872347.

6. Leung SF, Zee B, Ma BB, Hui EP, Mo F, Lai M, et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2006; 24(34):5414–8. doi: 10.1200/JCO.2006.07.7982 PMID: 17135642.

7. Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. The New England journal of medicine. 2004; 350(24):2461–70. doi: 10.1056/NEJMoa032260 PMID: 15190139.

8. Lo YM, Chan LY, Lo KW, Leung SF, Zhang J, Chan AT, et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer research. 1999; 59(6):1188–91. PMID: 10096545.

9. Lai SZ, Li WF, Chen L, Luo W, Chen YY, Liu LZ, et al. How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients? International journal of radiation oncology, biology, physics. 2011; 80(3):661–8. Epub 2010/07/21. doi: 10.1016/j.ijrobp.2010.03.024 PMID: 20643517.

10. Peng G, Wang T, Yang KY, Zhang S, Zhang T, Li Q, et al. A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology. 2012; 104(3):286–93. doi: 10.1016/j.radonc.2012.08.013 PMID: 22995588.

11. Shibutani M, Maeda K, Nagahara H, Noda E, Ohtani H, Nishiguchi Y, et al. Prognostic significance of the preoperative serum C-reactive protein level in patients with stage IV colorectal cancer. Surgery today. 2014. doi: 10.1007/s00595-014-0909-1 PMID: 24817059.

12. Yi JH, Wang D, Li ZY, Hu J, Niu XF, Liu XL. C-reactive protein as a prognostic factor for human osteosarcoma: a meta-analysis and literature review. PloS one. 2014; 9(5):e94632. doi: 10.1371/journal.pone.0094632 PMID: 24800842; PubMed Central PMCID: PMC4011684.

13. Sieghart W, Pinter M, Hucke F, Grazierdaei I, Schoniger-Hekele M, Muller C, et al. Single determination of C-reactive protein at the time of diagnosis predicts long-term outcome of patients with hepatocellular carcinoma. Hepatology. 2013; 57(6):2224–34. doi: 10.1002/hep.26057 PMID: 23961713.

14. Salazar J, Martinez MS, Chavez M, Toledo A, Anez R, Torres Y, et al. C-reactive protein: clinical and epidemiological perspectives. Cardiology research and practice. 2014; 2014:605810. doi: 10.1155/2014/605810 PMID: 24653858; PubMed Central PMCID: PMC3932642.

15. Xia WX, Zhang HB, Shi JL, Lu X, Wang L, Ye YF, et al. A prognostic model predicts the risk of distant metastasis and death for patients with nasopharyngeal carcinoma based on pre-treatment serum C-reactive protein and N-classification. European journal of cancer. 2013; 49(9):2152–60. doi: 10.1016/j.ejca.2013.03.003 PMID: 23571148.

16. Allin KH, Nordestgaard BG. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Critical reviews in clinical laboratory sciences. 2011; 48(4):155–70. doi: 10.3109/10408363.2011.599831 PMID: 22035340.

17. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003; 107(3):499–511. PMID: 12551878.

18. Torzewski M, Rist C, Mortensen RF, Zawka TP, Bienek M, Waltenberger J, et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arteriosclerosis, thrombosis, and vascular biology. 2000; 20(9):2094–9. PMID: 10978254.
31. Ma BB, King A, Lo YM, Yau YY, Zee B, Hui EP, et al. Relationship between pretreatment level of plasma Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer research. 1999; 59(21):5452–5. PMID: 10554016.

32. Liu ZQ, Chu L, Fang JM, Zhang X, Zhao HX, Chen YJ, et al. Prognostic role of C-reactive protein in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy: findings from a randomised trial. European journal of cancer. 2013; 49(8):1923–31. doi: 10.1016/j.ejca.2013.01.027 PMID: 23434149.

33. Quetier I, Brezillon N, Duriez M, Massinet H, Giang E, Ahodantin J, et al. Hepatitis B virus HBx protein impairs liver regeneration through enhanced expression of IL-6 in transgenic mice. Journal of hepatology. 2013; 59(2):285–91. doi: 10.1016/j.jhep.2013.03.021 PMID: 23542345.

20. Gauldie J, Richards C, Harrish D, Lansdorp P, Baumann H. Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proceedings of the National Academy of Sciences of the United States of America. 1987; 84(20):7251–5. PMID: 2444978; PubMed Central PMCID: PMC299269.

21. Huang PY, Wang CT, Cao KJ, Guo X, Guo L, Mo HY, et al. Pretreatment body mass index as an independent prognostic factor in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy: findings from a randomised trial. European journal of cancer. 2013; 49(8):1923–31. doi: 10.1016/j.ejca.2013.01.027 PMID: 23434149.

22. Xiao WW, Huang SM, Han F, Wu SX, Lu LX, Lin CG, et al. Local control, survival, and late toxicities of locally advanced nasopharyngeal carcinoma treated by simultaneous modulated accelerated radiotherapy combined with cisplatin concurrent chemotherapy: long-term results of a phase 2 study. Cancer. 2011; 117(9):1874–83. doi: 10.1002/cncr.25754 PMID: 21509764.

23. Lee NY, Terezakis SA. Intensity-modulated radiation therapy. Journal of surgical oncology. 2008; 97(8):691–6. doi: 10.1002/jso.21014 PMID: 18493919.

24. Wong FC, Ng AW, Lee VH, Lui CM, Yuen KK, Sze WK, et al. Whole-field simultaneous integrated-boost intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma. International journal of radiation oncology, biology, physics. 2010; 76(1):138–45. doi: 10.1016/j.ijrobp.2009.01.084 PMID: 19668284.

25. Xia WX, Ye YF, Lu X, Wang L, Ke LR, Zhang HB, et al. The impact of baseline serum C-reactive protein and C-reactive protein kinetics on the prognosis of metastatic nasopharyngeal carcinoma patients treated with palliative chemotherapy. PLoS one. 2013; 8(10):e76958. doi: 10.1371/journal.pone.0076958 PMID: 24130817; PubMed Central PMCID: PMC3794978.

26. Liu Y, Huang Q, Liu W, Liu Q, Jia W, Chang E, et al. Establishment of VCA and EBNA1 IgA-based combination by enzyme-linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a two-stage design with a preliminary performance study and a mass screening in southern China. International journal of cancer Journal international du cancer. 2012; 131(2):406–16. doi: 10.1002/ijc.26380 PMID: 21866545.

27. Chen L, Hu CS, Chen XZ, Hu GQ, Cheng ZB, Sun Y, et al. Concurrent chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. The lancet oncology. 2012; 13(2):163–71. doi: 10.1016/S1470-2045(11)70320-5 PMID: 22154591.

28. Strang F, Schunkert H. C-reactive protein and coronary heart disease: all said—is not it? Mediators of inflammation. 2014; 2014:757123. doi: 10.1155/2014/757123 PMID: 24808639; PubMed Central PMCID: PMC3997990.

29. Liu ZQ, Chu L, Fang JM, Zhang X, Zhao HX, Chen YJ, et al. Prognostic role of C-reactive protein in prostate cancer: a systematic review and meta-analysis. Asian journal of andrology. 2014; 16(3):467–71. doi: 10.4103/1008-682X.123686 PMID: 24589465; PubMed Central PMCID: PMC4023380.

30. Hu Q, Gou Y, Sun C, Ding W, Xu K, Gu B, et al. The prognostic value of C-reactive protein in renal cell carcinoma: a systematic review and meta-analysis. Urologic oncology. 2014; 32(1):50 e1–8. doi: 10.1016/j.uroonc.2013.07.016 PMID: 24239465.

31. Ma BB, King A, Lo YM, Yau YY, Zee B, Hui EP, et al. Relationship between pretreatment level of plasma Epstein-Barr virus DNA, tumor burden, and metabolic activity in advanced nasopharyngeal carcinoma. International journal of radiation oncology, biology, physics. 2006; 66(3):714–20. doi: 10.1016/j.ijrobp.2006.05.064 PMID: 17011447.

32. Lo YM, Leung SF, Chan LY, Lo KW, Zhang J, Chan AT, et al. Plasma cell-free Epstein-Barr virus DNA quantitation in patients with nasopharyngeal carcinoma. Correlation with clinical staging. Annals of the New York Academy of Sciences. 2000; 906:99–101. PMID: 10818603.

33. Leung SF, Chan KC, Ma BB, Hui EP, Mo F, Chow KC, et al. Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2014; 25(6):1204–8. doi: 10.1093/annonc/mdu117 PMID: 24638904.

34. Lo YM, Chan LY, Chan AT, Leung SF, Lo KW, Zhang J, et al. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer research. 1999; 59(21):5452–5. PMID: 10554016.
35. Chan KC, Zhang J, Chan AT, Lei KI, Leung SF, Chan LY, et al. Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer research. 2003; 63(9):2028–32. PMID: 12727814.

36. Mutirangura A, Pornthanakasem W, Theamboonlers A, Sriuranpong V, Lertsanguansinchi P, Yenrudi S, et al. Epstein-Barr viral DNA in serum of patients with nasopharyngeal carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research. 1998; 4(3):665–9. PMID: 9533535.

37. Eliopoulos AG, Stack M, Dawson CW, Kaye KM, Hodgkin L, Sihota S, et al. Epstein-Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-κB pathway involving TNF receptor-associated factors. Oncogene. 1997; 14(24):2899–916. doi: 10.1038/sj.onc.1201258 PMID: 9205097.

38. Liao Q, Zeng Z, Guo X, Li X, Wei F, Zhang W, et al. LPLUNC1 suppresses IL-6-induced nasopharyngeal carcinoma cell proliferation via inhibiting the Stat3 activation. Oncogene. 2014; 33(16):2098–109. doi: 10.1038/onc.2013.161 PMID: 23708661.

39. Atono Y, Sata M, Tanikawa K. Kinetics of C-reactive protein in acute viral hepatitis. Gastroenterologia Japonica. 1989; 24(6):655–62. PMID: 2514117.

40. Boncler M, Watala C. Regulation of cell function by isoforms of C-reactive protein: a comparative analysis. Acta biochimica Polonica. 2009; 56(1):17–31. PMID: 19219228.

41. Liu X, Li X, Jiang N, Lei Y, Tang LL, Chen L, et al. Prognostic value of chronic hepatitis B virus infection in patients with nasopharyngeal carcinoma: analysis of 1301 patients from an endemic area in China. Cancer. 2014; 120(1):68–76. doi: 10.1002/cncr.28377 PMID: 24114075.